東誠藥業(002675.SZ):控股子公司藍納成擬增資擴股引進投資者
格隆匯2月14日丨東誠藥業(002675.SZ)公佈,公司於2025年2月14日第六屆董事會第八次會議審議通過了《關於控股子公司增資擴股引進投資者暨關聯交易的議案》,同意公司控股子公司煙臺藍納成生物技術有限公司(簡稱“藍納成”或“目標公司”)以增資擴股方式擬引入溫州瑞力醫療新消費產業投資合夥企業(有限合夥)(簡稱“溫州瑞力”)、上海遴珏企業管理合夥企業(有限合夥)(簡稱“上海遴珏”)、上海瀚宸銘企業管理合夥企業(有限合夥)(簡稱“上海瀚宸銘”)3位投資者,東誠藥業參與本輪融資,4位投資者合計出資人民幣15,016萬元按照33.1040元/1元註冊資本出資額的對價認購藍納成新增的453.6006萬元註冊資本。藍納成本次增資擴股完成後,註冊資本變更爲人民幣8,911.7903萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.